Last updated: February 25, 2026
What is NDC 00075-8014?
NDC 00075-8014 corresponds to a specific formulation of a commercial drug. Based on available public records, NDC 00075-8014 is identified as Humira (adalimumab), a monoclonal antibody used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
Current Market Landscape
Market Size and Revenue
Humira is among the highest-revenue drugs globally, with estimated sales exceeding $20 billion annually before patent expiration. Its revenue peaked in 2018-2019, with sales reaching approximately $20.5 billion (IQVIA, 2022). The drug's blockbuster status results from its broad indication portfolio and extensive patent protection.
Patent and Regulatory Status
Humira's primary patents expired in the US in 2023, opening the market to biosimilar competitors. However, patent litigation and legal strategies delayed biosimilar approval in some markets until 2024. Several biosimilars are now entering the US and European markets, intensifying competition.
Competitor Landscape
Major biosimilar entrants include:
- Amgen's Amjevita (adalimumab-atto)
- Samsung Bioepis/Celltrion's Hadlima (adalimumab-bwwd)
These biosimilars are priced approximately 20-40% below the originator, affecting revenue streams for the original product.
Market Dynamics
The autoimmune biologics market is expected to Contract due to biosimilar penetration. Market research estimates a compound annual growth rate (CAGR) of approximately 4% from 2022 to 2027, driven by increasing diagnosis rates and expanding indications.
Geographic Market Trends
- United States: Large biosimilar entries pressuring pricing; originator revenues decline post-patent expiry.
- Europe: Earlier biosimilar adoption leading to significant price erosion.
- Emerging Markets: Growth potential due to increasing access and GDP increases, but affordability remains a barrier.
Price Trajectory and Projection
Historical Pricing Data
- US Wholesale Acquisition Cost (WAC): Approximately $5,600 per injection (single dose).
- European Average Price: Similar, with variations by country and healthcare system.
- Post-Biosimilar Entry: US prices declined by an estimated 25-35% within the first year of biosimilar availability.
Price Projection (2023-2028)
| Year |
Estimated Average Price (US WAC) |
Expected Market Share of Biosimilars |
Notes |
| 2023 |
$4,500 – $5,200 |
0%–15% |
Patent expiry; biosimilars entering |
| 2024 |
$4,200 – $5,000 |
20%–35% |
Biosimilar uptake accelerates |
| 2025 |
$4,000 – $4,800 |
40%–50% |
Market share stabilizes |
| 2026 |
$3,800 – $4,500 |
50%–60% |
Competition intensifies |
| 2027 |
$3,600 – $4,200 |
55%–70% |
Prices decline further |
| 2028 |
$3,400 – $4,000 |
65%–80% |
Potential additional biosimilar approvals |
Factors Influencing Price Trends
- Additional biosimilar approvals in the US and EU.
- Healthcare policy changes favoring biosimilars.
- Negotiation improvements by healthcare providers.
- Patent litigation outcomes affecting biosimilar market entry.
Revenue Projections
Assuming annual volume of 10 million doses domestically:
- 2023: Revenue drops from ~$56 billion (original pricing) to ~$45 billion.
- 2025: Revenue declines to ~$40 billion as market share shifts.
Global expenditure mirrors US trends but varies by region, considering different pricing and reimbursement structures.
Strategic Implications
- For manufacturers, biosimilar competition will pressure prices.
- Payers will continue to seek discounts; formulary preferences favor biosimilars.
- Innovators may pursue new indications or formulations to preserve market share.
Key Takeaways
- NDC 00075-8014 is identified as Humira, facing significant biosimilar competition.
- Market revenue is declining due to patent expiry and biosimilar entry.
- Price erosion projected at 25-40% over the next five years.
- Competitive landscape will be shaped by regulatory approvals and legal strategies.
- Emerging markets and new indications offer growth opportunities despite increasing competition.
FAQs
1. How will biosimilar competition impact Humira’s pricing?
Biosimilars are expected to reduce prices by 20-40% within two years of market entry, substantially lowering revenue per unit.
2. Are any legal or regulatory hurdles delaying biosimilar market entry?
Yes. Patent litigation and complex regulatory pathways can delay biosimilar approval, affecting timing and market penetration.
3. What is the future market outlook for adalimumab drugs?
Prices are likely to decline as biosimilars gain market share, but high-volume indications will sustain revenues, especially in emerging markets.
4. How do geographic differences affect pricing?
Europe generally exhibits lower prices and earlier biosimilar adoption, whereas the US maintains higher prices with slower biosimilar penetration.
5. Will innovation prevent revenue decline?
Development of new indications and formulations can mitigate revenue loss but may not fully offset pricing pressures.
References
[1] IQVIA Institute for Human Data Science. (2022). The Global Use of Medicines in 2022. IQVIA.
[2] FDA. (2023). Biologics Price Competition and Innovation Act of 2009.
[3] European Medicines Agency. (2023). Biosimilar Medicines.
[4] EvaluatePharma. (2022). World Pharmaceutical Market Trends.
[5] U.S. Patent and Trademark Office. (2023). Patent Data for Adalimumab (Humira).
